Ken Suzawa1, Junichi Soh1, Yuta Takahashi1, Hiroki Sato1, Kazuhiko Shien1, Hiromasa Yamamoto1, Susumu Kanazawa2, Katsuyuki Kiura3, Shinichiro Miyoshi1, Shinichi Toyooka4. 1. Department of Thoracic Surgery, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama, 700-8558, Japan. 2. Department of Radiology, Okayama University Hospital, Okayama, Japan. 3. Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. 4. Department of Thoracic Surgery, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama, 700-8558, Japan. toyooka@md.okayama-u.ac.jp.
Abstract
PURPOSES: The purpose of this study was to review the clinical course of patients with recurrence after induction chemoradiotherapy followed by surgery (trimodality therapy) for locally advanced non-small cell lung cancer (LA-NSCLC) and to identify the factors associated with favorable clinical outcome after recurrence. METHODS: We analyzed the records of 140 patients with LA-NSCLC who were treated with trimodality therapy between 1999 and 2014. RESULTS: Recurrence developed after trimodality therapy in 48 patients. A yp-N positive status was associated with a high risk of recurrence (HR, 2.05; P = 0.048). Of the 45 of these patients able to be assessed retrospectively, 18 had oligometastatic recurrence and 20 underwent local treatment with curative intent. Local treatment was most frequently given to patients with oligometastatic recurrence (P < 0.001). The median post-recurrence survival (PRS) was 41.4 months, and the 2-year PRS rate was 62%. Patients who received local treatment showed better PRS (P = 0.009). The presence of liver metastasis (P = 0.008), bone metastasis (P = 0.041), or dissemination (P < 0.0001) were associated with worse PRS. CONCLUSION: The survival of patients who received aggressive local treatment for postoperative recurrence after trimodality therapy for LA-NSCLC was better than that of patients who did not.
PURPOSES: The purpose of this study was to review the clinical course of patients with recurrence after induction chemoradiotherapy followed by surgery (trimodality therapy) for locally advanced non-small cell lung cancer (LA-NSCLC) and to identify the factors associated with favorable clinical outcome after recurrence. METHODS: We analyzed the records of 140 patients with LA-NSCLC who were treated with trimodality therapy between 1999 and 2014. RESULTS: Recurrence developed after trimodality therapy in 48 patients. A yp-N positive status was associated with a high risk of recurrence (HR, 2.05; P = 0.048). Of the 45 of these patients able to be assessed retrospectively, 18 had oligometastatic recurrence and 20 underwent local treatment with curative intent. Local treatment was most frequently given to patients with oligometastatic recurrence (P < 0.001). The median post-recurrence survival (PRS) was 41.4 months, and the 2-year PRS rate was 62%. Patients who received local treatment showed better PRS (P = 0.009). The presence of liver metastasis (P = 0.008), bone metastasis (P = 0.041), or dissemination (P < 0.0001) were associated with worse PRS. CONCLUSION: The survival of patients who received aggressive local treatment for postoperative recurrence after trimodality therapy for LA-NSCLC was better than that of patients who did not.
Entities:
Keywords:
Induction chemoradiotherapy; Local treatment; Lung cancer; Oligometastasis; Oligorecurrence
Authors: Dan J Raz; Michael Lanuti; Henning C Gaissert; Cameron D Wright; Douglas J Mathisen; John C Wain Journal: Ann Thorac Surg Date: 2011-09-22 Impact factor: 4.330
Authors: P S Billing; D L Miller; M S Allen; C Deschamps; V F Trastek; P C Pairolero Journal: J Thorac Cardiovasc Surg Date: 2001-09 Impact factor: 5.209
Authors: József Furák; Imre Troján; Tamás Szöke; László Agócs; Attila Csekeö; József Kas; Egon Svastics; József Eller; László Tiszlavicz Journal: Ann Thorac Surg Date: 2005-01 Impact factor: 4.330
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: H Katayama; H Ueoka; K Kiura; M Tabata; T Kozuki; M Tanimoto; T Fujiwara; N Tanaka; H Date; M Aoe; N Shimizu; M Takemoto; Y Hiraki Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640